In the last decade, RLT of prostate cancer with radiopharmaceuticals targeted at prostate-specific membrane antigen (PSMA) has gained increasing clinical acceptance and more recently, regulatory approval to treat advanced prostate cancer. The gene discussed is FOLH1; the disease is prostate carcinoma.